| Literature DB >> 29581989 |
Yamuna Deepani Siriwardana1, Bhagya Deepachandi1, Samantha Ranasinghe2, Preethi Soysa3, Nadira Karunaweera1.
Abstract
Visceral leishmaniasis (VL) is considered as a major health threat in the Indian subcontinent. Leishmania donovani, a usually visceralizing species, causes cutaneous leishmaniasis (CL) in Sri Lanka. However, visceralizing potential of the local L. donovani is not yet fully understood. This project studied the seroprevalence of local CL by using an in-house ELISA. An IgG-based ELISA using crude Leishmania antigen (Ag) was developed and validated. A total of 50 laboratory confirmed cases of locally acquired CL were examined using the newly developed ELISA. According to the optimized ELISA, seroprevalence of anti-Leishmania IgG antibodies in the study group was 34.0% (n = 17/50). Majority of seropositive individuals were males (n = 13/17), representing 76%. Nearly half of the seropositive individuals were young adults (20-40 years, n = 9/17, 53%). Higher proportions of single lesions, large lesions, and nodular lesions were associated with a seroconversion. A proportion of local L. donovani infections leading to CL have the ability to raise an antibody response in the host. This may indicate early systemic involvement as one possibility. Study of a large number of patients with adequate follow-up would be useful.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29581989 PMCID: PMC5822831 DOI: 10.1155/2018/9320367
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Distribution of enzyme-linked immunosorbent assay (ELISA) response of cutaneous leishmaniasis (CL), healthy control (HC), and non-CL (NCL) isolates. Positive control had a mean absorbance value of 2.400, while control samples, HC, and NCL had ELISA scores less than 1.456.
Figure 2Standard curve for positive control. The linearity of the assay was shown by coefficient of determination, R2 (=0.9962) calculated using the standard curve.
Comparison of ELISA results with LM.
| LM positive | LM negative | Total | |
|---|---|---|---|
| ELISA | |||
| Seropositive | 14 | 3 | 17 |
| Seronegative | 21 | 12 | 33 |
| Total | 35 | 15 | 50 |
Figure 3Receiver operating curve (ROC curve) analysis. Test sensitivity and specificity were 94.0% and 80.0%, respectively, at 1.308 cut-off level.
Serological response according to different clinical features.
| Clinical feature and category | Seropositive patients ( | Seronegative patients ( | Total ( |
|---|---|---|---|
|
| |||
| Northern | 6 (42.9%) | 8 (57.1%) | 14 (100%) |
| Southern | 9 (36.0%) | 16 (64.0%) | 25 (100%) |
| Other | 2 (18.2%) | 9 (81.8%) | 11 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
| |||
| Military | 6 (30.0%) | 14 (70.0%) | 20 (100%) |
| Civilian | 11 (39.3%) | 17 (60.7%) | 28 (100%) |
| Total | 17 (35.4%) | 31 (64.6%) | 48 (100%) |
|
| |||
| Up to 20 years | 3 (37.5%) | 5 (62.5%) | 8 (100%) |
| 21–40 years | 9 (39.1%) | 14 (60.9%) | 23 (100%) |
| >41 years | 5 (26.3%) | 14 (73.7%) | 19 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
| |||
| Male | 13 (32.5%) | 27 (67.5%) | 40 (100%) |
| Female | 4 (40.0%) | 6 (60.0%) | 10 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
| |||
| Single | 14 (37.8%) | 23 (62.2%) | 37 (100%) |
| Multiple | 3 (23.1%) | 10 (76.9%) | 13 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
| |||
| Up to 2 cm | 14 (46.7%) | 25 (53.3%) | 39 (100%) |
| >2 cm | 3 (27.2%) | 8 (72.8%) | 11 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
| |||
| Up to 3 months | 4 (30.8%) | 9 (69.2%) | 13 (100%) |
| 3–6 months | 7 (36.8%) | 12 (63.2%) | 19 (100%) |
| 7–9 months | 2 (28.6%) | 5 (71.4%) | 7 (100%) |
| 10–12 months | 4 (36.4%) | 7 (63.6%) | 11 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
| |||
| Papule | 1 (25.0%) | 3 (75.0%) | 4 (100%) |
| Nodule | 8 (47.1%) | 9 (52.9%) | 17 (100%) |
| Ulcerating nodule | 4 (30.8%) | 9 (69.2%) | 13 (100%) |
| Ulcer | 3 (30.0%) | 7 (70.0%) | 10 (100%) |
| Plaque | 1 (16.7%) | 5 (83.3%) | 11 (100%) |
| Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
Missing cases excluded.